| First Author | Waight JD | Year | 2018 |
| Journal | Cancer Cell | Volume | 33 |
| Issue | 6 | Pages | 1033-1047.e5 |
| PubMed ID | 29894690 | Mgi Jnum | J:262545 |
| Mgi Id | MGI:6162397 | Doi | 10.1016/j.ccell.2018.05.005 |
| Citation | Waight JD, et al. (2018) Selective FcgammaR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Cancer Cell 33(6):1033-1047.e5 |
| abstractText | The co-engagement of fragment crystallizable (Fc) gamma receptors (FcgammaRs) with the Fc region of recombinant immunoglobulin monoclonal antibodies (mAbs) and its contribution to therapeutic activity has been extensively studied. For example, Fc-FcgammaR interactions have been shown to be important for mAb-directed effector cell activities, as well as mAb-dependent forward signaling into target cells via receptor clustering. Here we identify a function of mAbs targeting T cell-expressed antigens that involves FcgammaR co-engagement on antigen-presenting cells (APCs). In the case of mAbs targeting CTLA-4 and TIGIT, the interaction with FcgammaR on APCs enhanced antigen-specific T cell responses and tumoricidal activity. This mechanism extended to an anti-CD45RB mAb, which led to FcgammaR-dependent regulatory T cell expansion in mice. |
